Technical Analysis for NXTC - NextCure, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.28 | -1.54% | -0.02 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | -1.54% | |
| 50 DMA Resistance | Bearish | -1.54% | |
| Calm After Storm | Range Contraction | -1.54% | |
| Inside Day | Range Contraction | -1.54% | |
| Oversold Stochastic | Weakness | -1.54% | |
| 20 DMA Resistance | Bearish | -2.29% | |
| 50 DMA Resistance | Bearish | -2.29% | |
| Pocket Pivot | Bullish Swing Setup | -2.29% | |
| Outside Day | Range Expansion | -2.29% | |
| Gapped Up | Strength | -2.29% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 1 hour ago |
| Down 1% | about 1 hour ago |
| 60 Minute Opening Range Breakdown | about 1 hour ago |
| 2x Volume Pace | about 3 hours ago |
| 1.5x Volume Pace | about 3 hours ago |
Get a Trading Sidekick!
- Earnings date: 10/31/2024
NextCure, Inc. Description
NextCure, Inc., a biopharmaceutical company, engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase I/II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression for the treatment of ovarian cancer, non-small cell lung cancer, and renal cancer. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is based in Beltsville, Maryland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immunotherapy Clinical Development Cancer Treatment Tumor Virotherapy Non Small Cell Lung Cancer Ovarian Cancer Small Cell Lung Cancer Oncolytics Biotech Tumor Microenvironment Metastasis Metastatic Solid Tumors Treatment Of Ovarian Cancer Halozyme Immune Related Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.57 |
| 52 Week Low | 1.03 |
| Average Volume | 36,171 |
| 200-Day Moving Average | 1.54 |
| 50-Day Moving Average | 1.36 |
| 20-Day Moving Average | 1.35 |
| 10-Day Moving Average | 1.35 |
| Average True Range | 0.09 |
| RSI (14) | 45.36 |
| ADX | 17.48 |
| +DI | 21.81 |
| -DI | 14.82 |
| Chandelier Exit (Long, 3 ATRs) | 1.33 |
| Chandelier Exit (Short, 3 ATRs) | 1.54 |
| Upper Bollinger Bands | 1.46 |
| Lower Bollinger Band | 1.23 |
| Percent B (%b) | 0.3 |
| BandWidth | 16.77 |
| MACD Line | -0.02 |
| MACD Signal Line | -0.01 |
| MACD Histogram | -0.0043 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.42 | ||||
| Resistance 3 (R3) | 1.43 | 1.41 | 1.40 | ||
| Resistance 2 (R2) | 1.41 | 1.38 | 1.40 | 1.39 | |
| Resistance 1 (R1) | 1.35 | 1.36 | 1.34 | 1.34 | 1.39 |
| Pivot Point | 1.33 | 1.33 | 1.32 | 1.32 | 1.33 |
| Support 1 (S1) | 1.27 | 1.30 | 1.26 | 1.26 | 1.21 |
| Support 2 (S2) | 1.25 | 1.28 | 1.24 | 1.21 | |
| Support 3 (S3) | 1.19 | 1.25 | 1.20 | ||
| Support 4 (S4) | 1.18 |
